Today: 28 June 2026
Browse Category

NASDAQ:IBRX 20 January 2026 - 27 June 2026

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
20 May 2026
·
ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio shares fell 21.1% Tuesday after the FDA posted a warning letter accusing the company of false or misleading claims about its cancer drug Anktiva in a TV ad and podcast. The FDA said the materials suggested Anktiva could cure or prevent all cancer, which is not approved. ImmunityBio has 15 working days to respond. Anktiva accounted for nearly all of the company’s $113 million in 2025 revenue.
25 March 2026
··
ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus

ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus

ImmunityBio shares rose 3.5% to $11.95 premarket Wednesday after reporting 2025 net product revenue of $113 million for Anktiva, up about 700% year over year. The company posted a 2025 net loss of $351.4 million and ended the year with $242.8 million in cash. Investors await a March FDA meeting on recombinant BCG. Director Barry J. Simon sold 175,000 shares last week under a prearranged plan.
25 February 2026
·
ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view

ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view

ImmunityBio shares rose about 1% to $8.70 premarket after reporting ANKTIVA net product revenue of $113 million for 2025, up roughly 700% from 2024. The company posted a $351.4 million net loss and ended the year with $242.8 million in cash. ANKTIVA is now authorized in 33 countries, including recent European approval. Traders are watching cash burn and upcoming regulatory milestones.
23 February 2026
·
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio shares (IBRX) closed Friday up 6% at $6.25, bucking broader market declines. The company faces dilution risk after amending a $505 million convertible note with Nant Capital. Attention is on FDA feedback for ANKTIVA’s label expansion in papillary bladder cancer, with a regulatory submission expected within 30 days. The next major event is the late-February ASCO GU conference.
1 February 2026
··
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio shares climbed 5.9% to $6.26 Friday, rebounding from early losses despite declines in major biotech ETFs. The move followed a STAT News report that Chairman Patrick Soon-Shiong misrepresented an FDA meeting on Anktiva’s label expansion. Investors also tracked dilution risk after ImmunityBio amended a $505 million convertible note to allow partial conversions into stock.
30 January 2026
·
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio shares fell 1.6% to $6.35 after a filing showed looser conversion terms on a $505 million note held by an affiliate of executive chairman Patrick Soon-Shiong. The amendment allows partial conversions into stock, raising dilution concerns. About 16.8 million shares traded as the stock ranged from $6.28 to $6.92. New glioblastoma data will be presented Jan. 31.
26 January 2026
·
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio shares fell 12.1% to $6.45 Friday after reporting median overall survival has not been reached in its Phase 2 glioblastoma trial. BTIG raised its price target to $9 and kept a Buy rating. The company said the FDA requested more data for its ANKTIVA bladder cancer application but no new trials. Preliminary 2025 net product revenue was reported at $113 million, up about 700% year-over-year.
24 January 2026
·
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio shares rose 2.7% to $7.54 Friday after updated Phase 2 data showed 19 of 23 glioblastoma patients still alive, with median overall survival unreached. Over 31 million shares traded as investors awaited more trial details at a Jan. 31 summit. The company reported 2025 ANKTIVA revenue of $113 million and year-end cash of $242.8 million. The stock has tripled in three weeks.
23 January 2026
·
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio shares fell 5.9% to $6.10 premarket after announcing an FDA meeting on possible resubmission of its ANKTIVA bladder-cancer drug. The FDA previously rejected the application for BCG-unresponsive papillary disease and has now requested more data. ImmunityBio plans to submit the information within 30 days. The company cites long-term trial data showing a 58.2% 12-month disease-free survival rate.
21 January 2026
·
1 2

Stock Market Today

  • Micron IPO: $1,000 Investment Now Worth Nearly $900,000
    June 28, 2026, 3:22 PM EDT. If you had invested $1,000 in Micron Technology at its June 1984 IPO, your shares would be worth approximately $890,657 today. Micron's stock price has surged to over $1,157 per share, boosted by three stock splits and strong demand in the memory chip sector. The company hit a $1 trillion market cap in May 2026, ranking among the world's 15 most valuable firms. Analysts forecast further gains, with price targets between $1,500 and $2,000. This performance represents an astonishing 88,966% return, underscoring Micron's dominance and growth in semiconductor markets over nearly four decades.

Latest articles

UiPath (NYSE:PATH) shares see heavy trading after Friday’s jump as buyback calculations come into focus

UiPath (NYSE:PATH) shares see heavy trading after Friday’s jump as buyback calculations come into focus

28 June 2026
UiPath closed up 6.04% at $10.53 Friday, with weekly trading volume equal to 57% of its diluted share count, but shares remain 8.2% below the company’s average first-quarter buyback price of $11.47; with $500 million authorized for repurchases, every $100 million at current prices retires more shares, making buyback efficiency a key factor as revenue and ARR growth remain in the low-teens.
Opendoor volume surpasses short interest after Russell 3000 addition

Opendoor shares face Russell 3000 test after 4.5x volume spike

28 June 2026
Opendoor Technologies (NASDAQ:OPEN) surged 448% above average trading volume Friday as its Russell 3000 inclusion took effect, with 171.65 million shares traded—exceeding total short interest and equaling 21% of public float—while the stock closed up 1.63% at $4.37; analysts maintain a Hold consensus and see limited rally potential near current prices.
Go toTop